Glycogen Storage Disease Type Ii
📧 Sign up to get email alerts when something new happens for Glycogen Storage Disease Type Ii.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2024-11-22EMA Authorised: Pombiliti (Cipaglucosidase alfa) — Amicus Therapeutics Europe Limited
The European Medicines Agency authorised Pombiliti (cipaglucosidase alfa) for Glycogen storage disease type II (Pompe disease) in the Europe…
-
EMA approval · 2024-08-16EMA Authorised: Myozyme (alglucosidase alfa) — Sanofi B.V.
EMA authorised marketing of Myozyme (alglucosidase alfa) by Sanofi B.V. for Glycogen storage disease type II (Pompe disease).
-
CLINICAL_TRIALS approval · 2014-02-06Clinical Trial Update: Alglucosidase Alfa Temporary Access Program
The document notes that alglucosidase alfa has received approval for a temporary access program with marketing approval for Pompe disease an…